A single β-amino acid substitution to angiotensin II confers AT 2 receptor selectivity and vascular function

Hypertension

Volumn 57, Issue 3 PART 2, 2011, Pages 570-576

  Jones, Emma S ^a   Del Borgo, Mark P ^b   Kirsch, Julian F ^a   Clayton, Daniel ^b   Bosnyak, Sanja ^a   Welungoda, Iresha ^a   Hausler, Nicholas ^a   Unabia, Sharon ^b   Perlmutter, Patrick ^a   Thomas, Walter G ^c   Aguilar, Marie Isabel ^b   Widdop, Robert E ^a  

^a MONASH UNIVERSITY   (Australia)

^b Department of Biochemistry and Molecular Biology ^*  (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

amino acid substitutions; angiotensin; AT2 receptor; depressor; vasorelaxation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II DERIVATIVE; BETA AMINO ACID; BETA ARGININE 2 ANGIOTENSIN II; BETA ASPARTIC ACID 1 ANGIOTENSIN II; BETA ISOLEUCINE 5 ANGIOTENSIN II; BETA PHENYLALANINE 8 ANGIOTENSIN II; BETA PROLINE 7 ANGIOTENSIN II; BETA TYROSINE 4 ANGIOTENSIN II; BETA VALINE 3 ANGIOTENSIN II; CANDESARTAN; N(G) NITROARGININE METHYL ESTER; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; ESSENTIAL HYPERTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RING; VASODILATATION;

AMINO ACID SUBSTITUTION; ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOOD PRESSURE; CELLS, CULTURED; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; IMIDAZOLES; MALE; MICE; NG-NITROARGININE METHYL ESTER; PROTEIN BINDING; PYRIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; VASODILATION;

EID: 79953216990     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164301     Document Type: Article

References (33)

1. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-824. (Pubitemid 37464062)
2. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.
3. Hannan RE, Widdop RE. Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. Curr Hypertens Rep. 2004;6:117-123. (Pubitemid 39359551)
4. Widdop RE, Vinh A, Henrion D, Jones ES. Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol. 2008; 35:386-390. (Pubitemid 351337334)
5. Porrello E, Delbridge L, Thomas W. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958-972.
6. Regoli D, Park WK, Rioux F. Pharmacology of angiotensin. Pharmacol Rev. 1974;26:69-123.
7. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
8. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284-291. (Pubitemid 19227303)
9. Aguilar MI, Purcell AW, Devi R, Lew R, Rossjohn J, Smith AI, Perlmutter P. B-Amino acid-containing hybrid peptides-new opportunities in peptidomimetics. Org Biomol Chem. 2007;5:2884-2890. (Pubitemid 47340677)
10. Steer DL, Lew RA, Perlmutter P, Smith AI, Aguilar MI. Beta-amino acids: versatile peptidomimetics. Curr Med Chem. 2002;9:811-822.
11. Aguilar MI, Fallon GD, Mayes P, Nordin S, Robinson AJ, Rose ML, Vounatsos F, Wilman B, Perlmutter P. The asymmetric imino-aldol approach to the enantioselective synthesis of beta-amino acids. Lett Pept Sci. 2004;10:597-604.
12. Lew RA, Boulos E, Stewart KM, Perlmutter P, Harte MF, Bond S, Reeve SB, Norman MU, Lew MJ, Aguilar MI, Smith AI. Substrate analogs incorporating beta-amino acids: potential application for peptidase inhibition. FASEB J. 2001;15:1664-1666.
13. Webb A, Dunstone MA, Williamson NA, Price JD, de Kauwe A, Chen W, Oakley A, Perlmutter P, McCluskey J, Rossjohn J, Aguilar MI, Purcell AW. T-cell determinants incorporating B-amino acid residues are protease resistant and remain immunogenic in vivo. J Immunol. 2005; 175:3810-3818. (Pubitemid 41292041)
14. Webb AI, Aguilar MI, Purcell AW. Optimisation of peptide-based cytotoxic T cell determinants using non-natural amino acids. Lett Pept Sci. 2004;10:561-569.
15. Webb AI, Dunstone MA, Chen W, Aguilar MI, Chen Q, Jackson H, Chang L, Kjer-Nielsen L, Beddoe T, McCluskey J, Rossjohn J, Purcell AW. The structure of HLA A2 complexed to peptides related to the tumor antigen NY-ESO-1 and the rational design of a new immunogenic analogue. J Biol Chem. 2004;279:3438-3446.
16. Steer DL, Lew R, Smith AI, Perlmutter P, Aguilar MI. Inhibitors of metalloendopeptidase EC 3.4.24.15 and EC 3.4.24.16 stabilized against proteolysis by the incorporation of beta-amino acids. Biochemistry. 2002; 41:10819-10826. (Pubitemid 34971059)
17. Qian H, Pipolo L, Thomas WG. Identification of protein kinase C phosphorylation sites in the angiotensin II (AT1A) receptor. Biochem J. 1999;343:637-644. (Pubitemid 29537376)
18. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension. 2005; 46:1347-1354. (Pubitemid 43189734)
19. Thomas WG, Motel TJ, Kule CE, Karoor V, Baker KM. Phosphorylation of the angiotensin II (AT1A) receptor carboxyl terminus: a role in receptor endocytosis. Mol Endocrinol. 1998;12:1513-1524. (Pubitemid 30663434)
20. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709-716.
21. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112-1116.
22. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142: 821-830. (Pubitemid 38998096)
23. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960-966. (Pubitemid 40628944)
24. Wan Y, Wallinder C, Plouffe B, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. (Pubitemid 39507341)
25. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschope C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlof B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-2532.
26. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482-1489.
27. Rosenstrom U, Skold C, Lindeberg G, Botros M, Nyberg F, Hallberg A, Karlen A. Synthesis and AT2 receptor-binding properties of angiotension II analogue. J Pept Res. 2004;64:194-201. (Pubitemid 39446661)
28. Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem. 1999;274:7103-7110.
29. Speth R, Kim K. Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine angiotensin II. Biochem Biophys Res Commun. 1990;169:997-1006. (Pubitemid 20220719)
30. Rosenstrom U, Skold C, Lindeberg G, Botros M, Nyberg F, Karlen A, Hallberg A. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II. J Med Chem. 2004;47:859-870. (Pubitemid 38176789)
31. Johannesson P, Erdelyi M, Lindeberg G, Frandberg PA, Nyberg F, Karlen A, Hallberg A. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem. 2004;47:6009-6019. (Pubitemid 39507342)
32. Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537-544. (Pubitemid 43843872)
33. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski M-C, Roques BP, Carey RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptorblocked rats. Hypertension. 2007;49:625-630.